Dec 19, 2022 7:00am EST Tonix Pharmaceuticals Achieves Enrollment of First 50 Percent of Participants in the RESILIENT Study, a Potentially Pivotal Confirmatory Phase 3 Study of TNX-102 SL for the Management of Fibromyalgia
Dec 12, 2022 7:00am EST Tonix Pharmaceuticals Announces Exclusive License of Potential Therapeutic or Preventative Humanized anti-SARS-CoV-2 Monoclonal Antibodies from Curia Global, Inc.
Dec 5, 2022 7:00am EST Tonix Pharmaceuticals Announces Collaboration with Boston Children’s Hospital to Study TNX-1500 (Fc-modified anti-CD40L mAb) for the Prevention of Graft-versus-Host Disease (GvHD) Following Hematopoietic Stem Cell Transplantation in Animals
Dec 1, 2022 7:00am EST Tonix Pharmaceuticals Presents Development Update on Potential Smallpox and Monkeypox Vaccine TNX-801 in an Oral Presentation at the World Vaccine and Immunotherapy Congress
Nov 30, 2022 7:00am EST Tonix Pharmaceuticals Announced Data from its Fully Human anti-SARS-CoV-2 Monoclonal Antibody Platform in an Oral Presentation at the World Antiviral Congress
Nov 22, 2022 7:00am EST Tonix Pharmaceuticals Announces Oral Presentation at the World Vaccine and Immunotherapy Congress
Nov 21, 2022 7:00am EST Tonix Pharmaceuticals Announces Oral Presentation at the World Antiviral Congress
Nov 16, 2022 7:00am EST Tonix Pharmaceuticals Announces Data from an in vitro Study of the Impact of Oxytocin on Human Neurons at Neuroscience 2022, the Annual Meeting of the Society for Neuroscience
Nov 9, 2022 7:00am EST Tonix Pharmaceuticals Announces Poster Presentation at Neuroscience 2022 by the Society for Neuroscience
